Thermo Fisher Scientific/$TMO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Thermo Fisher Scientific
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
- Ticker
- $TMO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 125,000
- Headquarters
- Waltham, United States
- Website
- www.thermofisher.com
TMO Metrics
BasicAdvanced
$257B
36.63
$18.97
0.88
$1.84
0.27%
Price and volume
Market cap
$257B
Beta
0.88
52-week high
$712.17
52-week low
$435.27
Average daily volume
2.3M
Dividend rate
$1.84
Financial strength
Current ratio
1.808
Quick ratio
1.226
Long term debt to equity
0.712
Total debt to equity
0.754
Dividend payout ratio (TTM)
9.52%
Interest coverage (TTM)
5.87%
Profitability
EBITDA (TTM)
12,197
Gross margin (TTM)
41.26%
Net profit margin (TTM)
14.94%
Operating margin (TTM)
19.20%
Effective tax rate (TTM)
9.48%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
5.23%
Return on equity (TTM)
13.38%
Valuation
Price to earnings (TTM)
36.629
Price to revenue (TTM)
5.455
Price to book
4.69
Price to tangible book (TTM)
-14.63
Price to free cash flow (TTM)
34.002
Free cash flow yield (TTM)
2.94%
Free cash flow per share (TTM)
20.433
Dividend yield (TTM)
0.26%
Forward dividend yield
0.27%
Growth
Revenue change (TTM)
8.27%
Earnings per share change (TTM)
9.54%
3-year revenue growth (CAGR)
2.93%
10-year revenue growth (CAGR)
10.17%
3-year earnings per share growth (CAGR)
7.53%
10-year earnings per share growth (CAGR)
14.26%
3-year dividend per share growth (CAGR)
10.87%
10-year dividend per share growth (CAGR)
11.86%
What the Analysts think about TMO
Analyst ratings (Buy, Hold, Sell) for Thermo Fisher Scientific stock.
Analyst projections of the future price of Thermo Fisher Scientific stock.
Bulls say / Bears say
Second-quarter revenue rose 10%, with 5% organic growth, and sales improved across all business segments. Thermo Fisher raised its 2026 profit forecast, suggesting the recovery in customer demand is feeding through to results. (Reuters)
Thermo Fisher’s broad reach across drug development could help it benefit as AI encourages more investment in research pipelines. Management says this opportunity supports its long-term target of 7% organic revenue growth a year. (Thermo Fisher Scientific)
India offers a potential growth runway: Thermo Fisher expects its customer base there to expand by 15% to 20% over five years, driven by investment in biopharma research and manufacturing, among other sectors. (Reuters)
Weak academic and government spending remains a drag in the US and China. In April, the CEO said Thermo Fisher did not expect those markets to recover this year, leaving an important source of demand subdued. (Reuters)
Tariffs and inflation linked to the Iran conflict threaten costs and margins. Management warned that some inflation might not be fully offset and built a buffer into its 2026 outlook. (Reuters)
HSBC downgraded Thermo Fisher to Hold, arguing that the 7% long-term growth goal needs more support. It also pointed to limited near-term organic growth momentum and uncertainty around outsourcing demand. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
TMO Financial Performance
Revenues and expenses
TMO Earnings Performance
Company profitability
Upcoming events
TMO News
AllArticlesVideos
Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings
Benzinga3 days ago
Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases
Business Wire4 days ago
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga1 week ago
Funds containing TMO
AllUSDEURGBP
Fund name | Fund size | $TMO weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector$XLVS | $552M | 4.00% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 4.00% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 3.73% |
SPDR MSCI World Health Care$WHEA | $708M | 2.75% |
SPDR MSCI World Health Care£HEAW | $708M | 2.75% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.